Who Qualifies for GLP-1 Weight Loss Medications? BMI Criteria, Insurance, and What Your Doctor Evaluates

Medically reviewed by the UT Cardiothoracic Surgery editorial team | Published April 2026

Disclaimer: This article is for educational purposes only and doesn't constitute medical advice. Eligibility for GLP-1 medications requires evaluation by a licensed healthcare provider. Insurance coverage varies by plan and isn't guaranteed.

Who Qualifies for GLP-1 Weight Loss Medications? The Complete Eligibility Breakdown

“Do I qualify for Ozempic?” “Can I get Wegovy if I'm not diabetic?” “Will my insurance cover it?” These are three of the most common questions patients bring to their doctors right now — and the answers aren't as straightforward as they should be. FDA eligibility criteria, insurance coverage criteria, and individual medical suitability are three different things, and understanding how they overlap (and where they don't) saves you time, frustration, and potentially money.

Let's walk through each layer so you know exactly where you stand before your first appointment. For the broader overview of all available GLP-1 medications, start with our complete GLP-1 guide.

FDA Eligibility Criteria: Who's Approved to Take These Medications

The FDA has established clear criteria for who can be prescribed GLP-1 medications for weight management. These criteria apply to Wegovy® (semaglutide) and Zepbound® (tirzepatide), which are the two GLP-1 medications specifically FDA-approved for chronic weight management:

Adults with a BMI of 30 or higher (classified as obesity) — no additional conditions required.

Adults with a BMI of 27 or higher (classified as overweight) who also have at least one weight-related medical condition. Qualifying conditions include type 2 diabetes or prediabetes, high blood pressure (hypertension), high cholesterol or triglycerides (dyslipidemia), obstructive sleep apnea, cardiovascular disease, fatty liver disease (NAFLD/NASH), and osteoarthritis related to excess weight.

Children aged 12 and older with obesity can be prescribed Wegovy for weight management. Children aged 10 and older with type 2 diabetes can be prescribed Mounjaro.

For Ozempic® and Mounjaro®, which are manufactured in an FDA-registered facility and follows Good Manufacturing Practice (GMP) standards for type 2 diabetes (not weight loss), the eligibility criteria are different — they're based on diabetes diagnosis, blood sugar levels, and whether other diabetes medications have been adequate. When these medications are prescribed for weight loss in patients without diabetes, that's off-label prescribing — legal and common, but it affects insurance coverage.

For the breakdown of how Ozempic, Wegovy, and Rybelsus differ despite containing the same molecule, see our semaglutide explainer.

Insurance Coverage: Where It Gets Complicated

Here's the frustrating reality: meeting FDA eligibility criteria doesn't guarantee insurance coverage. Insurance companies set their own coverage policies, and these are often more restrictive than the FDA's approval criteria.

Coverage for diabetes is generally better. If your doctor prescribes Ozempic or Mounjaro for type 2 diabetes management, most commercial insurance plans and Medicare Part D cover these medications with varying co-pays. The diabetes indication has been established longer, and payers have more established coverage frameworks.

Coverage for weight loss is more variable. Many insurance plans — including most Medicare plans and some employer-sponsored plans — specifically exclude weight loss medications from coverage. Even when plans do cover GLP-1s for weight management, they often impose additional requirements:

Prior authorization (your doctor must submit documentation proving medical necessity). Documented failure of supervised diet and exercise programs (typically 3-6 months of documented effort). Specific BMI thresholds that may be higher than the FDA's 27/30 criteria. Step therapy requirements (trying cheaper or older medications first). Quantity limits or duration restrictions.

The good news is that the landscape is shifting. As cardiovascular and metabolic evidence for GLP-1 medications strengthens — particularly the SELECT trial showing heart protection with semaglutide — more insurers are expanding coverage. Several states have passed or are considering legislation requiring coverage of obesity medications.

For detailed cost information including savings strategies, manufacturer programs, and the new oral Wegovy pricing, see our cost and access guide.

Who Should NOT Take GLP-1 Medications: Contraindications

This section is critically important from a safety standpoint. GLP-1 medications are not appropriate for everyone, and certain conditions represent clear contraindications:

Personal or family history of medullary thyroid carcinoma (MTC). All GLP-1 medications carry an FDA boxed warning based on thyroid C-cell tumor findings in animal studies. While this hasn't been confirmed in humans, patients with a history of MTC or the genetic condition multiple endocrine neoplasia syndrome type 2 (MEN2) should not take these medications.

History of pancreatitis. GLP-1 medications carry a risk of triggering pancreatitis, and patients with a prior history are at elevated risk for recurrence.

Severe gastrointestinal conditions. Gastroparesis (delayed stomach emptying) and inflammatory bowel disease may be worsened by GLP-1 medications, which further slow gastric motility.

Pregnancy or planned pregnancy. GLP-1 medications should be discontinued at least 2 months before a planned pregnancy. The effects on fetal development haven't been adequately studied, and pregnancy requires appropriate weight gain and nutrient storage.

History of eating disorders. The appetite suppression from GLP-1 medications can interact with eating disorder psychology in complex ways. Patients with a history of anorexia, bulimia, or other eating disorders should have a thorough behavioral health evaluation before starting therapy.

Type 1 diabetes. GLP-1 medications work on insulin-producing beta cells and are designed for type 2 diabetes, where insulin resistance is the primary issue. They're not appropriate for type 1 diabetes, where the body produces little or no insulin.

For the complete side effect profile and cardiac-specific considerations, see our side effects guide and our heart health article.

The Evaluation Process: What to Expect at Your Appointment

When you see a healthcare provider about GLP-1 medication, here's what a thorough evaluation typically includes:

Medical history review. Your provider will assess your weight history, prior weight loss attempts, current medications, family history (particularly thyroid and pancreatic conditions), and any contraindications listed above.

Physical exam and measurements. BMI calculation, waist circumference, blood pressure, and assessment of weight-related conditions.

Laboratory work. Blood tests typically include fasting blood sugar and HbA1c (to assess diabetes risk), lipid panel (cholesterol and triglycerides), liver function tests, kidney function tests, and thyroid function. These serve both to establish eligibility and as a baseline to track improvements on therapy.

Behavioral assessment. A good provider will discuss your relationship with food, eating patterns, mental health history, and realistic expectations for what medication can and can't accomplish.

Insurance navigation. Many practices have staff who can check your insurance benefits and help with prior authorization paperwork before you leave the office.

Who Can Prescribe GLP-1 Medications?

Any licensed healthcare provider with prescribing authority can prescribe GLP-1 medications — you don't need to see a specialist. This includes primary care physicians, nurse practitioners, physician assistants, endocrinologists, cardiologists, and bariatric medicine specialists.

That said, working with a provider experienced in weight management improves outcomes. They'll be better equipped to manage side effects, adjust dosing appropriately, monitor for complications, and integrate medication with the dietary and exercise modifications that maximize long-term results.

Telehealth providers also prescribe GLP-1 medications, including both brand-name and compounded versions. The quality and comprehensiveness of telehealth evaluations varies significantly between providers. For our analysis of the compounded medication landscape, see our compounded vs. brand-name guide.

Frequently Asked Questions

Can I get a GLP-1 medication just because I want to lose 10-15 pounds?

GLP-1 medications are FDA-approved for treating obesity as a chronic medical condition, not for cosmetic weight loss. If your BMI is below 27, you don't meet the current eligibility criteria. Even at BMI 27-29.9, you need a documented weight-related medical condition. These medications carry real side effects and costs — they're designed for patients whose excess weight poses genuine health risks.

My BMI is 29 and I have high blood pressure. Do I qualify?

You likely meet the FDA criteria (BMI ≥27 with a weight-related comorbidity). Whether your insurance covers it is a separate question that depends on your specific plan. Your healthcare provider can help navigate the authorization process.

What if my insurance denies coverage?

Your provider can file an appeal, often with additional documentation of medical necessity. Manufacturer savings programs (like Novo Nordisk's and Eli Lilly's) can significantly reduce costs for commercially insured patients. Patient assistance programs exist for qualifying uninsured patients. Compounded versions offer a lower-cost alternative, though with the caveats discussed in our compounded guide. See our cost guide for all options.

Can I stay on GLP-1 medications long-term?

Current guidance treats obesity as a chronic condition requiring ongoing management, similar to how hypertension or diabetes is managed. Many patients will benefit from long-term therapy. We discuss the implications of stopping therapy — including weight regain data — in our stopping GLP-1 medications guide.

For the complete picture of GLP-1 medications including how they work, which ones are available, and what the evidence shows, return to our complete GLP-1 guide.

This article will be updated as insurance policies and FDA criteria evolve. Last reviewed: April 2026.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before starting any new supplement or health program, especially if you have existing medical conditions or take prescription medications.